Xiaolin Zhu

Metabolomic biomarkers for hepatocellular carcinoma

Ningning Feng, Fatao Yu, Feng Yu, 2022, Medicine.

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

R. Bose, E. Small, S. Porten, 2023, Frontiers in Oncology.

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Julian C. Hong, M. Meng, R. Bose, 2023, Clinical genitourinary cancer.

Nanog-mediated stem cell properties is critical for MBNL3 associated paclitaxel resistance of ovarian cancer.

Xiaolin Zhu, Xueqing Sun, Guangying Cheng, 2021, Journal of biochemistry.

Ephrin-A4 Ligand (EFNA4) Predicts Poor Prognosis of Hepatocellular Carcinoma and Promotes Tumor Proliferation.

Zide Chen, Xiaolin Zhu, Xihua Fu, 2023, Journal of clinical and experimental hepatology.

A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy

Raunak Shrestha, N. Rydzewski, Meng Zhang, 2024, bioRxiv.